November 24, 2021
The first biosimilar of Novartis’ vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) in Japan, developed by Senju Pharmaceutical, will join the NHI price list on November 25, according to the government’s official gazette issued on November 24. Ranibizumab BS...read more